General Information of Drug (ID: DM8A120)

Drug Name
RO7121661 Drug Info
Synonyms RG7769
Indication
Disease Entry ICD 11 Status REF
Esophageal squamous cell carcinoma 2E60.1 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM8A120

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis A virus cellular receptor 2 (TIM3) TT1RWL7 HAVR2_HUMAN Inhibitor [2]
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Programmed cell death protein 1 (PD-1) DTT PDCD1 5.635 4.661 4.706 5.15
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Esophageal squamous cell carcinoma
ICD Disease Classification 2E60.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04785820) A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus. U.S. National Institutes of Health.
2 Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.